Navigation Links
U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Date:2/27/2012

short time before any surgery, medical or dental procedure. Your doctor will tell you when to start taking XARELTO® again after your surgery or procedure.
  • Do not run out of XARELTO®. Refill your prescription for XARELTO® before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO® available to avoid missing any doses.
  • If you miss a dose of XARELTO®, take it as soon as you remember on the same day.
  • If you take too much XARELTO®, go to the nearest hospital emergency room or call your doctor right away.
  • WHAT ARE THE POSSIBLE SIDE EFFECTS OF XARELTO®?

    XARELTO® can cause bleeding which can be serious, and rarely may lead to death. Please see "What is the most important information I should know about XARELTO®?"

    Tell your doctor if you have any side effect that bothers you or that does not go away.

    Discuss any side effects with your doctor. You are also encouraged to report side effects to the FDA: visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc. at
    1-800-JANSSEN (526-7736).

    Please click here for full prescribing information, including Boxed Warnings and the Medication Guide. Trademarks are those of their respective owners.

    (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements
    '/>"/>

    SOURCE Janssen Research & Development, LLC
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. FDA Grants Petition for Removal From Import Alert
    2. FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension
    3. FDA Grants 510(k) Clearance to Curos® Disinfecting Port Protector
    4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    5. US Patent Office Grants COPAN Invention of Flocked Swabs
    6. The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
    7. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
    8. FDA Awards NIPTE Potential $35 Million in Grants to Reform Drug Manufacturing Process
    9. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    10. Pevion Grants CSL Option Right to its Therapeutic Candida Vaccine
    11. Muscular Dystrophy Association Awards $13.7 Million for 40 New Research Grants
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... and HOUSTON, TX , ... the "Company") (TSX-V: EPI) and Bloom Burton & Co. ... from voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares ... Common Shares originally subject to the Lock-Up. Of the ... be free trading immediately upon release from the Lock-Up ...
    (Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
    (Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
    Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
    ... N.C., Dec. 21, 2010 Charlotte Business Journal ... an affiliate of Diagnostic Devices Inc. – one of ... an awards luncheon held at the Charlotte Convention Center ... recognizes Charlotte area companies for their leadership, entrepreneurial excellence, ...
    ... 21, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... Executive Officer, will host a conference call and webcast tomorrow, ... a.m. Pacific Time) to provide an update following the completion ... Administration (FDA) for the lorcaserin New Drug Application (NDA). ...
    Cached Medicine Technology:Charlotte Business Journal Honors Prodigy Diabetes Care, LLC With Fast 50 Award 2Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 2Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 3
    (Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
    (Date:2/28/2015)... With their commitment to achieving physical ... additional exercise to their already robust library of oblique ... commonly known as, is often performed on a stationary ... in a relatively safe manner and can be performed ... full description of “Rope Pulls” is located in the ...
    (Date:2/28/2015)... 28, 2015 March—also known as ... to remind ourselves and others that suspected head ... NeuroSurgical Specialists (ANS). , Concussions are a form ... 75% of TBIs. There are 1.6-3.8 million sports-related ... benign, but it is a brain injury. Many ...
    (Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
    (Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
    Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
    ... HealthDay Reporter , FRIDAY, Aug. 13 (HealthDay News) ... acetaminophen, best known as Tylenol, were more than twice ... take the over-the-counter pain and fever reducer, new research ... increased chance of eczema and rhinoconjunctivitis, or allergic nasal ...
    ... to adopt electronic medical records helps speed adoption by ... in the current issue of Management Science , ... and the Management Sciences (INFORMS)., "Social Contagion and Information ... U.S. Hospitals" is by Corey M. Angst and Ken ...
    ... Institute for Environmental Education and Research is helping ... local workers to create a pool of green ... and energy efficiency. A handful of local ... a U.S. Labor Department Energy Training Partnership grant, ...
    ... of Medicine today announced that the National Institutes of ... of Food Allergy Research (CoFAR), providing an additional $29.9 ... of food allergy. Mount Sinai is the primary research ... country. Under the renewed grant, Mount Sinai researchers ...
    ... Glioblastoma multiforme is the most common form of brain cancer; ... on diagnosis, the chances of survival of the patient is ... known nor the manner to prevent it. What is more, ... in 40 years, unlike other cancers such as, for example, ...
    ... LOS ANGELES (Aug. 11, 2010) Understanding the underlying genetic weakness ... and provide the key to effective treatment, a new study ... an investigational drug, Olaparib, can reduce the size of tumors ... mutations. The Phase II ovarian cancer ...
    Cached Medicine News:Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 2Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 3Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 4Health News:Speed electronic medical record adoption via key medical centers, says Management Science 2Health News:Carnegie Mellon's Steinbrenner Institute helps grow green jobs 2Health News:Mount Sinai leads Consortium of Food Allergy Research with $29.9 million grant 2Health News:Multidisciplinary treatment of glioblastoma multiforme can extend patient's life 2Health News:New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer 2
    ... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
    ... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
    ... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
    An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
    Medicine Products: